CX3CL1 and atherosclerosis: Furthermore, the presence of fractalkine in atherosclerotic plaques and involvement in atherosclerosis makes our fractalkine-targeted PA nanofiber a unique avenue for investigation to prevent restenosis in the setting of atherosclerosis.